Siemens Healthcare GmbH QSJM Responsible Third Party Official · registration, listing of devices,...
Transcript of Siemens Healthcare GmbH QSJM Responsible Third Party Official · registration, listing of devices,...
U.S. Food & Drug Administration 10903 New Hampshire Avenue D o c I D # 0 4 0 1 7 . 0 2 . 0 8 Silver Spring, MD 20993 www.fda.gov
Siemens Healthcare GmbH℅ Mr. Alexander SchapovalovResponsible Third Party Official 510(k) TPR Deputy Program ManagerTÜV SÜD America Inc.1775 Old Highway 8 NWNEW BRIGHTON MN 55112-1891
Re: K180563Trade/Device Name: syngo®.plazaRegulation Number: 21 CFR 892.2050Regulation Name: Picture archiving and communications systemRegulatory Class: Class IIProduct Code: LLZDated: April 11, 2018Received: April 16, 2018
Dear Mr. Schapovalov:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
Page 2 – Mr. Schapovalov K180563
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([email protected]) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Robert Ochs, Ph.D.DirectorDivision of Radiological HealthOffice of In Vitro Diagnostics
and Radiological HealthCenter for Devices and Radiological Health
Enclosure
FORM FDA 3881 (7/17) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120Expiration Date: 06/30/2020See PRA Statement below.
510(k) Number (if known)K180563
Device Namesyngo®.plaza
Indications for Use (Describe)syngo .plaza is a Picture Archiving and Communication System intended to display, process, read, report, communicate, distribute, store, and archive digital medical images, including mammographic images. It supports the physician in diagnosis and treatment planning For primary image diagnosis in Mammography only uncompressed or non-lossy compressed images and only preprocessed DICOM "For Presentation" images must be used. Also monitors (displays) and printers which received FDA clearance for Mammography must be used syngo .plaza also supports DICOM Structured Reports In a comprehensive imaging suite, syngo .plaza integrates Hospital/Radiology Information Systems (HIS/RIS) to enable customer-specific workflows syngo .plaza optionally uses a variety of advanced postprocessing applications
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human ServicesFood and Drug AdministrationOffice of Chief Information OfficerPaperwork Reduction Act (PRA) [email protected]
“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”
2%risersK 5%%Wm
Traditional 510(k) Summarvsyng0®.plaza VB30
This summary of 510(k) safety and effectiveness information is being submitted inaccordance with the requirements of SMDA 1990 and 21 CFR §807.92.
1. SubmitterSiemens Healthcare GmbHHenkestrasse 12791052 ErlangenGermany
2. Establishment Registration Number
3002808157
3. Contact PersonVij ay RamadasRegulatory Affairs ManagerSiemens Healthcare GmbHHartmanstrasse 1691052 ErlangenGermanyTelephone: +49 172 432 4369Telefax: +49 (9131) 84-8691Email: [email protected]
4. Device Name and ClassificationProduct Name: syng0®.plaZaClassification Name: Picture Archiving and Communications SystemClassification Panel: RadiologyCFR Section: 21 CFR §892.2050Device Class: Class IIProduct Code: LLZ
5. Legally Marketed Predicate DeviceProduct Name: syng0®.plaza510(k) Number: K132532Clearance Date December 09, 2013
6. Safety and Effectiveness Information Supporting the Substantial EquivalenceDetermination
6.1 Intended Use
syng0®.plaZa is a Picture Archiving and Communication System intendedto display, process, read, report, communicate, distribute, store, and archivedigital medical images, including mammographic images. It supports thephysician in diagnosis and treatment planning
For primary image diagnosis in Mammography only uncompressed or non-lossy compressed images and only preprocessed DICOM "For Presentation"
510(k) for syng0®.plaza Page J-1
Y:zt1%iv
rL
F
2
1£1ii\ta
i1tli
»
E1i2i
Ii
\1l
1
T1i
l
5
©Siemens Healthcare GmbH, 2018
images must be used. Also monitors (displays) and printers which receivedFDA clearance for Mammography must be used
syng0®.plaza also supports DICOM Structured Repoits
In a comprehensive imaging suite, syng0®.plaza integrates Hospital / RadiologyInformation Systems (HIS / RIS) to enable customer specific workflows
syng0®. plaza optionally uses a variety of advanced postprocessing applications
6.2 TechnologicalCharacteristicssyngo®.plaZa is a “software only”-system, to be installed on common IThardware, matching the syngo®.plaza hardware requirements.
The above characteristics are also applicable for the predicate devicesyngo®.plaZa VBl0A (K132532)
Page J-2 510(k) for syng0®.plaza
2tFYt
v¢§
I2
2‘l
»»I
t
1I1
2“fig§_%®§§EGU;HOSUOHQ21‘MOas®>fiO0’u®
E8bag05%g%HOSagaHO:8%gwwgsmick
b:2OE__HaBa6Esmw26EaE26figOPE26WQEHOQOM80¢\O:flgOfiOq_@
wqEO%HO5wfifiugfis
\£Bgggmg’OwggmapdoHmgM_é>%%O§a
06OHUOHMQEOQgagomm>EE26figE8320$3wEtOgOH0%Dmggg
_:M=_EgN§‘sk\N°®NQE&§_NBSMN§_E=N_E£G&€§Egg|fi\&__20>?I “Pq®EOHfiHm
DMDUOUGOPE2:Egaugemg@580?O668>5
B3:8gwgfi__GO%E0m®€__Om___EOOHQUOWMOOOEIEQfigcgmfiwdg8mmoaEOO%mmO_|qO_HHOEmm®aaOg5fig%£gNHwOEE®2E
mmmOgw£U“figbflacm“Om
_wEg%Pgapgb
cgmmmO_H_wfi%E§Da€D6mtO_E5m“H_m®wNEM
OEEEMOEHEEWQMUHQOHHM“mmvwfiamjéga_gw%
£208fig“OHOHWflgspgwmv"BHNOESEEOQQHOQDH“$2"wm80a“\€_%%OHUOGEDHQM
eggwQOENOESEEOU
Mugwézog
2305Gmm_§Na_®OwsAm
Bagegwdwew__gO€E®m2mHg:EOOHQ8mm8Oa|PafigE8gwfiwamUDWWOHQEOO%mmO_|gOgHO_Bmm®aEOOgfig%£mflHw0EEfi2E
WMWOGWBUOmgsbaamaHOHH
_wE€%E0635
EamWmOgw2UE652.92%D6mtOnE:m“H_m%§E
OMJQMHMOEEQEwEU:_OE“mpwga_8%®EEfiwsu
$50:fig“agmdH__5Em%“QHGOMESEEOOQOQE“U63hmm®OOaggmmzuOPgags
639$QOMEOEDEEOU
fig@5224
353$Qmw§%~@Owfi%
OWDBqqgfi
<2
OwcgoHegofligzENOQ
mgOfi_\__Om
E82U<gag
®HNO£Q_®®mm:DEO@w
Hohaofisgg
_ SgngS_mmgoggamgpbgwm
___SSSGOEBMDQSSS7_m8g®$m5
W
SNoqmm>_gH_n__@ow&m
n<2m_>flN£m_®QM$@M_v2>%%%a2:OHomgNN2HH_®QM_g@_COUEOQm®Og_E'g_DDEmmésmg“EggwE\$O:O%Dfi
DataQgflmuohmEahgsfiwiQ®EQn_smm___aEOO“ObflaaiwS
MWSN“EEG§O£_8mWEEBWQ
\/
d§a_@QMsQH8COO_WfllDwmm
<2Dag
_Oo80_aQOMKOESQFQOOEgqfimfignu\mgovamfloooaoaMHOEOEEgggm
_OO8OagO€UE5EaOOEgqgmE5E\NSFBEMSOOHEQMHOEOGEggfiw
GOENOEDEEOO
0&5
<228%
QM
IXEaEEOMQED"M2“PO
Nam
Iv“USNESOWNED“M2“HO
MBEGUOEU8_HO%Fm
_ME_E2~_E‘BR
__§§§EBxMN§Q_Q3H~_N&M‘_NNQNMQEN~§M§~|€\§‘$82
_aO§N£m%wEmm8Oa|__mOn‘_
U8g>%W0bfiggN
was%=§__0umONN_N_m_@Owg$
_m>>OmV__HO>>
OgggmHOEOHMDO03202$2\mg23%__O%E‘_OwE__§wO_O%sH
:fiEmOmmggwga_w§__H_®Ow§m“£3
wawflg®>mmflDJDHnHEOONHmQ25Bgogm285mtogaom?wNm_m_@ow§m63:2age%:gfiHwOEEN2
he®OgNHN2UIR;gzgagigagiafigAm\€_%%V
mH8EOaOWEflow:
_mgO€O:m%wEmm8OH&mOm
80mg?““OEOE;M
was%=®qO$QO§a_@Owg
_maOfiHOB
Ogggm(56035028808$2\mgmagiEOMHQQCOEHH_8mmO_O%_§
:g%OmmggwggmH~§_m_®OwgAm“£5
wigs®>mmG2__®_aEOOMSgagUoéogm285mtgaaom?wN2Q_@OmsAm_Bm5B5:8\€%%OaEN2
HO,“OOGESE‘GAEU0>MOQ®H£05?WRDHQEQfigAmbwamflvv
WHOPEOEOmzfigs
_ mmOQ®>€®_,wm__UgbfldmmgqpfigaEmwfififiaamwQUNQEH__A____ ccufihomooy__
W q q m%g%§_g_®og
l>uSagwNda_@ow§m__
MNSN“EEGgoggm§E2m©
‘g
‘VK_V>H'_’/‘xuhuv/VF/fig”jg/’7ig_Q_//‘‘I‘)1MW"HN“WvHgbVEvrFVE“fité>bnvVqA»§“P‘_1:“V\V\Vv‘\VyVV _V_a3_I__V“L_‘_AI1II___Y‘L__77V?!E
WHowgwNma_@°M$@Ha23$
Owcgo
<2On“bigoHeU®mNEm®m
H0668¢§_m_OwEnmDams
BawggfigwEEOQQ
2065P26EEBMS:0w£>EgEagxm
033$ESPWGOQowgfi
<208%
figmggggm
__~Em:_v£_mE2@AmEaO_n__N_:__wmgOoQ0OMEOHW
gag_NEO§mEaRaga
figmgggsm
Ebmgfi_mE8w%mQé03E5wmgOOGOowggm
gagfiggmm“ENE538
®wfi_HOHmEBBtO_(_mOwgfi
<208$
gagHgmazI
_U®>6Oa
mfiggamwfi‘mil
©2600“
MNw®%_W_%%‘Um“:%mmOQI
QOQNom“:
mmgmmg
I83gm“:mmgmggI
Um”:
mmgwmgIom“:mmgmgqI
Um“:
mmgmwg3%m$aEOOgDIAm<Z=0$3wE>EO_€
BOMBEaAgévow2OH_mGOMOHNSHOEgOWwm®aEOo
fig_m$_m8_Um“:
tagmmlwmgI
8388
mfl©Q€_%€‘ImiI
@3608
3wPQ_%%‘IUm“:%mmO‘H1
QOONmug:
mmgmmg
IOOONgm:mm2mmOAI
um“:
mm2mmO~IUm“:WWBMWOQI
GMT:
wmgmmgI%mm8mEOOgDIAm<ZCO$3wE>EOH_W
883EaflagOwggmGOMOHNH085“gOMmm®_aEOQ
apt’?@@®i@O_
GOEWDHQEOO8%035
fiN2m_@O%SQ2&535HOW_880_aHamggowgg
fig_gOE%<Q/HOOHQ
HN§a_@Qm=\®DgmfiasH8_OOOH_O_HmHflmgb“$25
58?:OE%<AZOOHQ
_ __Hogaa(_‘I ‘_(Iqommgmum__Vmmm5i>€®mm_ug_b&dm‘7mouflogotgawgmouugamm
68>_N%_@Ow%
MWSN“mafiaBSHESE§E2m©
QN@E_®QMs@HQQ3fl®
@A0%“
HOSUOHQ05MOas®>E&%UgflEggO5OwggoHO
HOMQEMHOE3%Bgmsmmfi
U3N©g§%%O%€Og_wEE20G05d3%§_NmwgmagBDQD8E
30%O5W0fiéagUgggEN8,“Sag_WN£m_@OwShm
0%figMMOEO
%=$OfiQgHOP5NE23EH
“E36BEmwgEmsN555
35:0
wGEOgUM_N§_Q_@OwgAmHOWgomgabfivQHNEOWHGUSU
%agD\B%gD
238084figCOSDQEMWU2§£OmE26“€>O_aEH
Gofiags
E26
<2
“Ham
mcOESmV_HO>>
HGOQGDQOUQMHgaoflggg
“wagm>>OUE>?
mgO§Hm%O>>
Egugggm§_aO&5§E
“U32m;O©E>?
ggpwgm
HO:_DO_:MEHMOgs®>€®mOEabagD5%§_OHO
gaawHOE3%2%“;Eat
GOu3OmgygwgaHOMHB0520OH826
39$gagmE$282
_H_>3Hv_HO>>®EQH_m_
E8_ugw%“$605HE“51EmgggfimQM>
__“#_>®1mMHOBOENHWE
8_§_w%“E005ESmmgggfim2>“8>O_aEH
GOENOEBEIE8ma
<Z
08%
2>_@QM$®
£>_@QMg@
mésgEma
<2
08%
H_O€gmMEEU_Ngm:gN:_g%O
QOQEEEEESm:8N%fi5U
goggm
IMGMEUNamp
£9“mggcfim
EEMBEH_®>EP_<askmg“:ScamEGHOUSpa8HOmaagm%SOH_mms/H
gm?mggggmEEWBV5
_®>EoH<EOEwQOQ
EOUHQE885\&EUd8HOmaggmDwggmmg/HB66OHwggfigwQ~N2g_@OwgAm
( ((BQQEH(N%g0>%ummfigbygm
7_( =(2(EEmZ0Q
(7 MQUQUMDIHEQgmmgfiggm
Hmmfigflig§_Q_®ow&m
’jogfi%_@o§
MWSN“mpgBNOHENQEEOEOEQ
V
ZOmg
§mE_®°M$QHQ25$
E;Vt“L“KLAl4.'\’W>kVgV',VVF__‘\/:3‘‘“‘‘‘ ‘‘H‘‘fl_Rg&HE€‘“&‘Ly,r§N:;*£h6UV
HO:©O'HgQt(HOas2£O®w®figEggO6OwcgoHO
Sag:“Om3%BggWEB
€mi®>cg@®Hg0E®_mg
gm;mGO€wE2
fig“EMHQUUm\A_MENgm;QOEEOEBQEW>52EamH5e®>Oa8H
05=<gm:25Qt
82230EOE®E>OacgDQQNEHOEDQEggmgags
8DEEgmmag?an
EHaflflflm.
vwvgw82&5.gumEém.>5;SMOH.ago;<8‘
gbv
OfimOMOQHOJHOSPHNU.
QOEQEBH
$80\w£_Ofi_Hfi“Ham0
b_%HwOEeH~2
HO,“tagwaOEHOB.GOQNEO£82Eghm.
%wO_O%E2®H.
WEHEE.
€O§0mmO>mm.8Og%<GmOw;0
OwmdmmmOwgm.
imam5&5
MOMQED;“H§E_____H.
Q/OE80$
MOEOEGOgmgHgofiEOONgw:<nH§6_aEH.
gigsQMEfi
£>_Owshm“u0>O_:::H.
WEUNOQ
®>@mm2wO§"$02.
EEofim.
MofimGO0&4.U8“gwam.82>aim;.§$2><mQ.
Age
OfimOMONHOGHOSUHNO.
OOG0H£®M
mmeo\wE$%_HOamm.
%£mMHwOEE®2
MOMtO&:mgO§HOg.GOENOHO$82ub0E_\mm.
%wO~O%§_£.
WEHEE.
€®z0mm0>mm.gO§%<QMOmg.
RamGmOwg.
EEEOSOQE82m%Oa\DMNMOE
gO%Q:fiE<
v_AHOMQEH_m$m0>€Nmmfigfigmm
7 j j_§%o_mU_QII moogofigggwmoflummggm
_cgfi%_@Ow%
MWSN“WEEGQanggm§E2w©
/LT
dNNE_®QMS@H8CO2W
W%Dmg
<2
lmmeuv:O€®__O§QMQSEGQHQW_DfimGOU32
UwfigQMEN95gas05,HOm2g%HO|OOBUMw_H%G:OD
gagu©QH_N:_O_flOV
A%£mQHwOEE®§VH_OEw__6__NOQOMMUMfig“?
§
08$____E_sw_<Q>_§E__§_U
lmweovqO€0_8&gm@235_%EGOwag
QwgagEfigDams06W083520-00“DOMwH:Ug:OO_
E2582%3_“___U__W&
A%£gfiHwOEEN2VQOSBSOEOQgwqmgflaa
_____F6w_¢Q>$fl::_N:Q
afifiowz
mam
ImgemOWN?
<2
55$Aim.
Qibv
OfimOmoG_HO____HOmvgo.
gggwfié
mmgo\w_H=g_fi“Ham.
%Jm8wOEEfie
HO“tgasm>>O¢%O>?.
wgiggm.
£02_0mm0>Gm0=O€_EmgO8mmm.
ogwmagi_
Hgag<mQ.
9:8
Ofim2022?OMUHNO.
OOQQHOHHM
$80\wE_2§gam.
%£m$HwOEEG6
HOWtgaim>>OE%O>?.
w€®UGOm'
“£62_®m$>gm.QOSOPBMGOODMmm.
magi.
wEmw8OE
Dwfig
wfiggbmEwawEaGEOE52%§O_aEH.
iOMHGNMgOEU&mmggm“_U?s_aEH.
mMm0£P§mOEOF
_ _ (8&5 (_0cofigtumughmHmHH__MH_‘_‘_‘fi_WH(__ _?Ngggmfigbog_moogamga€_§E§gmVHm i_Ai<oH_§ggowgm
7OMQ/i§_Q?_@ow§m_
MWSN“E986guggm§E2m©
méown.““N63@°MS@HowEvan
Abwmfiwi_8%_Q0gmg
OmfigHaENOH“gag0%MOm3g%HO|OO“gmwagfig
gag;“UQHfl_:U_NOV
¢£%_HwOEE2>©gOflfi_5o_$UCOM?“
Abmmflfiam_3€_GOgmg
Owgfi5Efiggmmu0%MOWOHMQMUMOIOOHOQMmG:UqDO&
EBEMEE%8fl_:O__3V
A%£mfiHwOaE&2VgOfi_28__®OCOED“
QwgsQNSSm_O%§WS
EOSSDQO
OEENDEMOEsWQMEOMHQQH8’?aO©§vugmfi5
Owfig‘HOadoEMOQgflzwUsQ0qOEmOg>5268N___U_NOV
§_E8§_OM\E®n<EOONVqO$QgO%wG®HHgE<mom5%6EEMWGOHE
“EmaDwgfiGOEgg
$22igumfismH__8_W__5__8V
mgjg“ahaEsefigzHOE2852“_HO$§>0DEmdma0><'HOGO%_5_8
MOMm§fiOm_<HoflmgmA353_gOwO£tOEEOGOBaa25EOHM830%w®QO£_O_§HUs'8mgNE€OIOUH__8N___O__8VQoggpfim
NMQSNQN~QN§§N§wE
QHOSQHQQO
Dag“ECONQHMWCMQHHOIHHOAHhug“KOUGMK_UQ€_%%E
OwgfiMO03$ESQgzwDeMOGOEMOQ>52HH_8_W___U__3v
§E\8gOM\g£\EOONVQOflNg:O’Hmqm_H_HgE<COMSawNEbmmggi
mamaUwgfiGOgmgr
$3?_dOfimfi8w63_w___O__wUV
$2?gag533%;HOE2352“gOfi£>®gEmdwEg<MO:O%_5_8
MOMma£EOw_<_§_m§wAgga?qOwO£_HOH2tOQO“Egg26EOQmasg§O%aD6'8mD§bEOIOU“€g__6__“OVAUOQOHNHDM
Mmw®g®>u8mmV WOUQQHUEWQ“HAHN _ MHeap:M _M gggamg
__W_¢gm>M§H@M@ow&m_
Om?§_m_@ow&mM
MNSN“EEGgO§_w£m_8e2m©
_\
S%_@°M§5g2@EADwfi
Eggmgamg:OE05EQEB2%“2;Hgwfia
mafia
E6figism59,32250%‘HO£w_8_O5Ea02$“Hag_3%_DNHNEMGOgagGO€_:O__8QEOQNGQUEOQEfiapamsgasHOOGSMMQ
EOURHOQO
2&62:0E8wgE_HO't&SgwgOUEUygamflvE
Uwflg‘HOQuaESQsaw05'38&8“>902Hfl_8_“___O_8V
@E\gO%_gEOONV=OflN§OMmg®HH2&4momsawQEbMmQ®pgM
ExaOmgfiGOwag
wgig_8umuSw%8N_:O__8v
mg?’“yaeafivazHOggg“QOfig>®QEmdw§>/$0gO%_a_8
HO“mEH_EOw_<jgmgmQOENE_§HOwO£_HOH050GO0&32580¢mUbMOQUSOOFE2:Usm®H§H:BOIOU“H_8N___O_8VADOGDHDMDM
ImmeovQOMHOOFEgm
EUgsmgamg:OED58352Ema2;H2&2
MEMOQ
UsU5tgmQOOEOD3:06MO5?“:0%Ea03$wfioam“vxaOwgaQ0wagQOMHESOEOgagN50253EOa8a82asHDogma
EOEHKO
“EEGD6MOpawgamptasawaOUaa_U®%2%%5
DwflafiMO03$QGMOQ5%D5W0ggmg>62%8_w___U__8V
@_h€§OM\EN&EOONvqOflGgbO'Hmqfl_H__H254GO“53%NEbmmqgfi
_8"EDwfigGOBmg
m®:1N>_NOfimfifiHmn_%§___O__8V
83?“lama825%;HOEEEEEEOMERUQEmdw20><W0qO€_5O_g
HO“mE£EOw_<TNOSMENHWAgga_gOwOfiEO$60GO05326E8“mH£OmUDHOUHOHQO6MO$8820‘O0%3_W___O__8v®OG®_H®’%®Am
lmmeovQOfiO£'OHnHGm
_ (AUQQEHV Gomatomommwgogouganbog?moogohgagméggmMM___WiAW_M_m_i§_M@WW§_Aw@Ow%jfigmN%_@ow§m
MWSN“EEG$06?“M5826
L
HHIHowfim32%®QM§whe98$
Agfig_2_gaOH_U28__OagamgOHMHg“822_9s>EgggsEEEMQE
MOH_Og~N%am>Hm_8_N___O__8V
GOMHODEOHAHbwmgopa
5%;EaEsgxfiz
Amoga
GGOWOHUHO8&0“OmowgaH_O_Em:OO88gm:P8233
25EmflwfigH_H_8N__8_8V_HOuO5H_mqOOO‘mggfiagg
figa$2888_UBO®__OaBag,OSHEP822_§O>EEEEEfigesangz
UsGO€N:gmM>%8_N___U__8v
GOSODFHQbwmggfi
E2882EaEaavgg
Amgfim
_gOwOfiEO6&0'HOgwggHOPUMGOODH8Em:pa22%28Em®wd§HH_3_N___O_8VQOUOPSWEOODMMEEWEEBE
__~GRQ\H\£QQEQUNNQNGQMS
E___:__¢w_<wE__Q_=$m
_§_m_Ow§m5mEDaD;mgE
0§_O>Ogu QEgammaEa
Dag"286figEggDe_HO_*qOuG_:O_dOqO$£>®QEggfiwEaOBSEMNEEsgégfigESEMEE
6me0><HD_wfi§_ODM“£86“OwHOHQEEOQ
MEfiOMHfi__‘_U_NO9;UHDFQEMHOAM2w_§O3_£55“£86MO83MOgOfi®_:Q_NO2;“QUE
gOflOOH:VOMEOOMOIMHQQ
kggS§O_c§Q_~NQmGQMS
E__:_~Ow_<wflmsuflgm
$N2m_OwgAmEmE®EP5m8E
DE3O>OnHgdE__®Oc§mR_fig
Daam“B86DEWE2&8QtH8QOSSBOROgOMH2>0QEgggm“END32fixaEBEENEfigE588?/H
6wE®><UDHWQSODM“B86HO,“Hgbaig
MBQOUEDOEO“EHfigBwcgbqmflnwaam“£86‘HON98‘HOcO€_€__82;%
ggwggu0mM>§OOG|u§
mwg®>€mNwmb®%©wm8%.$'EQ“G6 _>__I Egg__ vgougumogj
é_
LfignN%_@ow8nm
MWSN“£60P8228:m=®E2m©
]L\
/
wNmE_@°Mg®H8QuaWvs‘Hown“
Am0§EvHO
I852%05GOEWMCOHGM_8"awags“H__8_N___U_8VHawmgOwE>?mam:\n£QmE
OwghBgphgoHBIMW
AESCONE0585QOEggkgmagg_9mEUgwgfimmUHvQtw_:O_flOVAwgEHOOEmV
_HO€_O&OEmU555
AEJEOMEHNOGWEQQ0wagbwmfifiEaUD3§EHH_8“___O_svAwcEHOOEmV
qOflN_O&®#gMHsgmm€EEOw_QHDOOEMMDG
#382=0wagbangsEfimBfiwgammH_v8_“___U__3V
AwE£HOOEwVggggga
EOAEMBZIHWOGOZ
A2E__O>QMwpsggoofigm‘HOg%Nm_gmm>Hm_3_W__8_8V
\€_%R_gflgwwfiggw
Ag5_O>gmMO_HOfiNN:6:mM\/
"%§___O_8Vgggfiorfi
MEOUGOM0E30>
AWOHQEMUHO
I888%05GObfimflfipaExaUEOHVQOMHH_3_W_3__NOVR6maOUg;?wag%2%%
OM68“DEOQAOHUHEIMW
QHHGEHOWED585GOEmg\£mg8EENEUgwagmHH_8_w___O__3VAwE£OOEmV
qO%_O&3E058$
A§EO%_§®E_5Q0BmgbMmg®#gMEfimwgwafimmHU3N_5__W&AmE§OOEmV
gO%_O&BEgmvqgmAQEEOENHDODJMEG
“mafiaSQOWNDbmmggaENEU8_gEmmu__3_N___O__3V
AwE€OOEmVGO%_O&8E
§O£%$Z.Hm®H8z
M
®E3O>gmUOHOUQDH0O@5m06gO€N:gmm>H__8_W__5__8v
gammagfigmUggm
@E5_O>mmW0GO%Nm_gmm>
UH6:W_=U__wOVOSUMEOQH
w€0wg®mOE3O>
( ‘ I( _SMQEHV7_ggommm__A(vmmogzpoolwmEdbflfiw((mmogmhmmmgmgmmfigmgm(
% jjfigNN%~@oM%_
MWSN"EEGggggmWQOEOEQ
_\IVVVVL
2;0%“;‘mNNE_®°m=_A__nHggag
EavimMOM8mbg_®mg;
E8050%MO33ggflwnoE®E®>Oa_E2;gm;UsEsbfifimD5%ggQHO058MGOEHHO£05D353
sag“HOG$20EggME;O“2&5OHMmgwggEH
30:0MQEOQOME
M576gfimgflWMMEHHOQUM
witagHO,“gm:B
8UOHEOHEpgmmE020fig
Q:égofigCH®_%%g088MMwGEO%HW36damEaE5OHmam:O5m>>O%EaE26fig“_UQ>Q_::=H
E2690>?
<205$
wqaggm839$IE_U_g_m_UHQEOWI
mhgagw
mat’UOUQOEEOOUMIH_Ou&HOgHag5&0‘;I
wigfigmEggmlE2OBm3§£OmI
mgggm
25>EUQUEEOOOMIgOSgCOc®fig’EWOQI
\£M_H:O®w‘gnaw
AbmggfififimBEE
gagO5wapgbgmHog“bfiqga_8"E%8_w___O_8V9&8_HO€_Nbfi_:m“$5
QVOHOUHHOH
BG8fig?HQQEOMMamaOHE3500figGOQQEHOMEHHSqgafigfimoflHug[:5HO>a0flagqOfi@gGO'HmENhbmmflgiExaum_8_fl___O__8V
$58025EggH5EWGEOEE
AWQBEEO
I882%05GOb§_8EGig8H%8Mu_§\_N___U__8V
R6mBOUE>>wig
bN_%%Owga528PBlg
@285Bigmama
M352:wngspgmHangkgmggfi_gE%3N___O_8vQflmgcOۤbr_)_m%g_
Qugggg
BE8figsKamaHBMNH8E8500EaQOSNHHGOIHGMFD‘;gO€B5m3m_Ears:HO>GOwaggO§EHO'Hm§bbmmgflpfiENEH_§\_“___O__3V
AwEgOE_§/VEggH5EaWQEOEM3
QBBEEO
'8580m05GObmwggfimamaUOHOUGOMH%§___O_3V
R6m>POUE>>mam:
gammaOwgsE28#5Ix
_J ’_ PONQEH_;é V___g%@uw®Qmwmgzsommfigbmkwmmoaokmfiaasmughgawm
_;NM“;_”M@ g;§E¢®ow&m
__08>mVN%A@ow§m
MWSNH586OEOHESE_§E2m©
§mE_®°M=®HQ£2WSADmvg
<2
Pogoa06
H:mO$:dgO:_Og5%goOZOGOZOQOZ
guzgogqsm
as
<2
ggsmg
OZmgfigOHNEOW
w5mm8Oa|H_mOm0:5MmmQ252262
m8m>®QwE§5g®U
035GO8&5
E26WGEOQBHMagus0%3Dag
OHMmgO%wE2wingEH_EmE®>HugUDEMVEBQEM
E26NGSHOQDM
WEEK”D5Emfl08%
89$EOEQNEEmmEGNGOSOGEWQEOQE
’?mmggU8’um_figbmgw
(_Egg;
(____H_ogE§H_-fly( VN
mogefign€2®E§§m_§a_@ow%?jjagdN%_@ow%i
fig“E380OEOSEOE€®82m©
8
9
1
1
00
1.
©Siemens Healthcare GmbH, 2018
Clinical Testing
No clinical studies were carried out for syng0®.plaza, all performance testing wasconducted in a non-clinical fashion as part of the verification and validationactivities fir the medical device
Non-Clinical Performance Testing
The software verification and validation was performed for the complete systemaccording the following standards:
- ISO 1497l:2007- IEC 62304 Edition 1.1 2015-06
- IEC 82304-1 Edition 1.1 2016-10
- IEC 62366-1 Edition 1.0 2015-02
- NEMA PS3 /ISO 12052:2017 (DICOM)- ISO / IEC 10918-l:1994 + TC l:2005
- ISO / IEC 15444-l:2005 + TC 112007- IEEE 3333.2.l:2015
- ISO /HL7 2l73l:2014 (HL7 Version 2.x)
After comparison of the test results with the software release acceptance criteria,Siemens Healthcare GmbH is of the opinion, that syng0®.plaza VB30 issubstantially equivalent to and performs as well as the predicate devicesyng0®. plaza VB 1 OAGeneral Safety and Effectiveness Information
The device labeling contains instructions for use and necessary cautions for safeand effective use of the device. Risk Management was implemented throughoutthe development process to control potential hazards
The device does not come into contact with the patient and is only used by trainedprofessionals. Risk management is ensured via a risk analysis, which is used toidentify potential hazards. These potential hazards are controlled via softwaredevelopment, verification and validation
Siemens Healthcare GmbH believes that syng0®. plaza VB30 is safe and effectiveas the identified predicate device and does not introduce new safety andeffectiveness concerns
Substantial EquivalenceThe syng0®.plaza, addressed in this premarket notification, is substantiallyequivalent to the following commercially available device:
Manufacturer Predicate Device FDA Clearance Number i Clearance Date
Siemens AG Healthcare syng0®.plaza VBIOA Kl32532 i December 09, 2013
The syng0®. plaza described in this 510(k) has the same intended use and similartechnical characteristics as the predicate device listed above in regard to thespecific functionalities.
510(k) for syng0®.plaza Page J-15
t1I
£-i
e
IZ
s
©Siemens Healthcare GmbH, 2018
12. ConclusionIn summary, Siemens Healthcare GmbH is of the opinion that syngo®.plaza VB30does not introduce any new potential safety risks and is substantially equivalent to andperforms as well as the predicate device.
Page J-16 510(k) for syng0®.plaza
9t
2§E1
Q
r
ii
2
I
Ir;
li
Ill»
iiI?
Er
F
E;1:
&2Iiiifr
ifZ:r:K
ti;:
,.1/.vz3
I2
la‘I
I31
l
lls
,.
%
5Y.,
5
Dl
lall